Fig. 1

CXCR2 is associated with tumorigenesis and poor prognosis. a GEO dataset analysis of expression of CXCR1 and CXCR2 in nevi as compared to melanoma lesions (not significant, Welch's t-test). b GEO dataset analysis of expression of CXCL1, CXCL2, CXCL3, CXCL5 and CXCL8 in nevi and melanoma tissues (significance determined by Welch's t-test). c Overall survival plot of melanoma patients from the TCGA SKCM dataset indicates significantly improved survival (p = 0.035, log-rank test) in the lowest quartile of CXCR2 expression (blue, n = 107) compared to the highest quartile (red, n = 114). d Analysis of survival of 25 melanoma patients treated with anti-PD-1 in relation to high (red) or low (blue) expression of CXCR2 [p < 0.01, log-rank test; [27]]. e Re-analysis of the Riaz RNA-seq database shows CXCR2 expression is lower in melanoma patients who responded to anti-PD1 treatment (p < 0.05, Welch's t-test)